Answer
Eravacycline may prolong prothrombin time (PT) and activated partial thromboplastin time (aPTT), and hypofibrinogenaemia has been reported; coagulation parameters, including blood fibrinogen, should be monitored before treatment and regularly during treatment.
Sources for this answer
- Xerava 100 mg powder for concentrate for solution for infusionPAION UK Ltd · emc · SmPC §4.4 Special warnings and precautions for use · Version 3Document updated
Sources checked